Viking Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Zelin from BTIG reiterated a Buy rating on the stock and has a $125.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Justin Zelin has given his Buy rating due to a combination of factors that highlight Viking Therapeutics’ strong positioning in the obesity and metabolic disease market. The recent acquisitions by large pharmaceutical companies, such as Pfizer’s acquisition of Metsera, underscore the strategic importance and high valuation of companies in this sector. Viking Therapeutics is seen as one of the few remaining independent players with a mature and advanced portfolio, making it an attractive target for partnerships or acquisitions.
Viking’s competitive edge is further strengthened by its differentiated programs, including the VK2735 with potential monthly dosing and an amylin agonist IND expected in late 2025. These developments enhance Viking’s appeal for favorable financing and partnering opportunities. Additionally, the scarcity of late-stage metabolic players positions Viking to benefit from increased investor focus and strategic interest, justifying its premium valuation. These factors collectively support the Buy rating and the positive outlook for Viking Therapeutics.
According to TipRanks, Zelin is a 3-star analyst with an average return of 3.3% and a 34.50% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Verastem, Viking Therapeutics, and Jasper Therapeutics.
In another report released on September 8, Piper Sandler also maintained a Buy rating on the stock with a $71.00 price target.